Researchers today unveiled results from a new blood test to help identify which patients are at an elevated risk of Alzheimer’s disease. The findings, presented at the 68th AACC Annual Scientific Meeting & Clinical Lab Expo in Philadelphia, showed that the biochip test, which allows multiple tests to be run on one blood sample, was as accurate as existing molecular tests that analyze DNA.
“This is the first time that we have used this biochip technology to test for an increased risk of Alzheimer’s disease,” said Emma C. Harte, PhD, a research scientist at Randox Laboratories. “This type of testing is important in our quest to understand and diagnose Alzheimer’s and empower patients to understand risks, consider medication, and even make early lifestyle changes.”
This test detects the presence of a protein in the blood produced by a specific variation of the apolipoprotein gene (ApoE4), which is associated with increased risk of developing Alzheimer’s disease. The apolipoprotein gene is inherited from each parent and when a patient inherits the ApoE4 variant from one parent they have a three times greater risk of developing Alzheimer’s disease, whereas a patient who inherits ApoE4 from both parents is eight-to-12 times more likely to develop the disease.
Accuracy of test
To verify the accuracy of the biochip test, 384 samples were analyzed and results compared to those from a standard molecular diagnostic test. Researchers from Randox Laboratories collaborated with research colleagues at the Medical University of Vienna and found that results from the two tests were in 100% agreement. As biochip tests allow clinicians and researchers to quickly run multiple tests on one sample of blood, this new test is also faster and more affordable than the standard DNA test, producing results in only three hours. This enables doctors to predict the risk of an individual developing Alzheimer’s disease.
“Pairing this test with medical and family history for risk of Alzheimer’s disease has the real potential to advance personalized medicine,” said Harte. “This fast, accurate testing will allow doctors and patients to make more informed choices earlier to potentially slow the possible progress of Alzheimer’s.”
In addition to this study, researchers will present the latest in Alzheimer’s disease at the AACC Annual Scientific Meeting & Clinical Lab Expo, including:
- New research explores using the level of angiotensin-converting enzyme (ACE) in the brain and spinal cord as a biomarker for neurodegenerative diseases, including Parkinson’s disease and AD. “Cerebrospinal Fluid Angiotensin-Converting Enzyme Activity Levels of Patients With Alzheimer’s and Parkinson’s Disease” (A-118)
- Researchers have shown that a specific protein in blood plasma could serve as a biomarker for early detection of AD. “Plasma neuron derived exosomal protein biomarkers in the diagnosis of Alzheimer’s Disease” (A-135)
- A new meta-analysis of studies over 12 year suggests that a possible relationship between thyroid function and an increased risk of dementia. “Higher FT4 or TSH Below the Normal Range are Associated with an Increased Risk of Dementia: a Meta-analysis of 10 Studies” (A-180) – USNewswire